Navigation Links
FDA Approves Gleevec For Expanded Use in Patients With Rare Gastrointestinal Cancer
Date:1/31/2012

SILVER SPRING, Md., Jan. 31, 2012 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today's action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the standard 12 months of treatment.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Gleevec was originally granted accelerated approval for the treatment of advanced or metastatic GIST in 2002. In 2008 Gleevec received a subsequent accelerated approval for adjuvant use that is for the treatment of patients with GIST who had had potentially curative resection (surgical removal) of GIST tumors, but who were at increased risk for a recurrence. The accelerated approval program provides earlier patient access to promising new drugs while the confirmatory clinical trials are being conducted. Regular approval for the metastatic GIST indication was also granted in 2008.

GIST is a rare form of cancer that originates in cells found in the wall of the GI tract. These cells, known as interstitial cells of Cajal, are part of the autonomic nervous system, which regulates body processes such as food digestion. More than half of GISTs start in the stomach.

"The development of Gleevec over the past decade highlights the need to further study drugs after approval to truly characterize their benefits," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "Although originally approved in the metastatic disease setting, this subsequent trial has demonstrated that longer use of Gleevec can prolong patient's lives in earlier disease settings."

The label is being updated to include clinical data from a large randomized clinical study comparing 12 to 36 months of Gleevec. Thirty-six months of Gleevec significantly prolonged overall survival and the time a patient lived without the disease recurring, compared to those receiving 12 months of Gleevec. At 60 months, 92 percent of patients who received 36 months of Gleevec were alive compared to 82 percent of patients who received 12 months of Gleevec.

Gleevec is a pill that should be taken with a meal and a glass of water.

The most common side effects observed in patients receiving Gleevec include swelling (edema), nausea, vomiting, muscle cramps, bone or muscle pain, diarrhea, rash, fatigue, and abdominal pain.

Gleevec was first approved by FDA in May 2001 to treat patients with advanced Philadelphia chromosome positive chronic myeloid leukemia, a blood and bone marrow disease linked to a genetic abnormality.

Gleevec is marketed by Novartis Pharmaceuticals Corp. based in East Hanover, N.J.

For more information:

FDA Approves Gleevec to Prevent Recurrence of Rare Gastrointestinal Cancer (2008)
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116997.htm

FDA Office of Hematology and Oncology Products
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm091745.htm

FDA Approved Drugs: Questions and Answers
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Stephanie Yao, 301-796-0394, stephanie.yao@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis
2. ASAM Approves Prescription Drug Policy
3. FDA Approves Picato® (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
4. FDA Approves Shared REMS (Risk Evaluation and Mitigation Strategy) Program for all TIRF (Transmucosal Immediate Release Fentanyl) Pain Treatments
5. FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension
6. FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure
7. FDA Approves Hologics Cervista High Throughput Automation System for Cervical Cancer Screening
8. FDA Approves First Generic Version of Cholesterol-Lowering Drug Lipitor
9. FDA Approves First Insomnia Drug for Middle-of-the-Night Waking Followed By Difficulty Returning to Sleep
10. FDA Approves Eylea for Eye Disorder in Older People
11. FDA Approves First Supplemental Test for Chagas Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 Research and Markets has announced the ... their offering. ... R&D Drug Pipeline Database: 1-Year ... Drug Pipeline Database provides 24/7 online access to information about more ... and on investigational drug candidates in research & development. ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, un líder mundial ... el INSTI HIV Self Test , a los miembros de la Kenya ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue ...
(Date:12/2/2016)...  LifeVac, the revolutionary device that has successfully rescued ... Training and Support Services (ERTSS) training programs. ... part of the ERTSS mission to save lives," said ... "Having an established network of expert trainers demonstrating how ... our efforts to spread LifeVac,s message that choking deaths ...
Breaking Medicine Technology:
(Date:12/2/2016)... AL (PRWEB) , ... December 02, 2016 , ... ... from across the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF ... Schmitz, will help provide scholarship funds for area students and operating support to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related ... those affected by autism spectrum disorder (ASD) and other developmental disabilities. The group, which ... give parents and other caregivers the opportunity to share stories and advice, seek help, ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 02, 2016 , ... ... high school and while 84 percent of parents report speaking with their child about ... pornography and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
Breaking Medicine News(10 mins):